Interleukin-20 as a Target in Psoriasis Treatment
: Interleukin‐20 (IL‐20) is a new member of the IL‐10 cytokine family discovered by a structural algorithm. IL‐20 transgenic mice displayed skin abnormalities reminiscent of psoriasis, a finding that has prompted the investigation of this new interleukin in relation to this disease. This article re...
Gespeichert in:
| Veröffentlicht in: | Annals of the New York Academy of Sciences 2007-09, Vol.1110 (1), p.368-381 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 381 |
|---|---|
| container_issue | 1 |
| container_start_page | 368 |
| container_title | Annals of the New York Academy of Sciences |
| container_volume | 1110 |
| creator | STENDERUP, KARIN ROSADA, CECILIA WORSAAE, ANNE CLAUSEN, JES THORN NORMAN DAM, TOMAS |
| description | : Interleukin‐20 (IL‐20) is a new member of the IL‐10 cytokine family discovered by a structural algorithm. IL‐20 transgenic mice displayed skin abnormalities reminiscent of psoriasis, a finding that has prompted the investigation of this new interleukin in relation to this disease. This article reviews the role of IL‐20 and its implication in psoriasis. It is shown that IL‐20 and its receptors are found in human skin and that IL‐20 is involved in proliferation, angiogenesis, and chemotaxis, all characteristics of psoriasis. We demonstrated that IL‐20 induced the thickening of human epidermis in vivo; however, this thickening does not seem to be related to a direct effect of IL‐20 on hyperproliferation since the growth of normal human epidermal keratinocytes (NHEKs) cultured in vitro was not affected by IL‐20. On the other hand, in vitro, IL‐20 stimulated human peripheral blood mononuclear cells (PBMCs) to produce proinflammatory cytokines and, in vivo, IL‐20 in combination with PBMCs induced psoriasis. This may suggest that IL‐20 indirectly exerts its proliferative effects on keratinocytes via immune cells present in the skin. Finally, we found that blocking IL‐20 signaling in psoriasis improves psoriasis, suggesting that IL‐20 is a potential target in psoriasis treatment. |
| doi_str_mv | 10.1196/annals.1423.039 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_68337203</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>68337203</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4749-9d4c669f0c9ba0dde69cbfa683e9e09e1ae4a9d6fd27a181b375cfe86c388d1d3</originalsourceid><addsrcrecordid>eNqFkMFPwjAUhxujEUTP3sxO3gZ97WjXI6AiCUETUeOp6bY3MxkD2y3Kf-_miB459fL9vtd8hFwC7QMoMTBFYXLXh4DxPuXqiHRBBsoXgrNj0qVUSj9UjHfImXMflAILA3lKOiAVQDBkXQKzokSbY7XKCp9RzzjPeEtj37H0ssJ7dBubGZc5b2nRlGssynNyktY38WL_9sjz3e1ycu_PH6azyWjux0HzBZUEsRAqpbGKDE0SFCqOUiNCjgqpQjAYGJWINGHSQAgRl8M4xVDEPAwTSHiPXLferd18VuhKvc5cjHluCtxUTtcmLhnlB0FGh4oF0ICDFoztxjmLqd7abG3sTgPVTU7d5tRNTl3nrBdXe3UVrTH55_f9aoC3wFeW4-6QTy_eRk-_Wr9dZa7E77-VsSstZN1Bvy6mmoIcT8YvNzrkPyeOkEk</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>20592413</pqid></control><display><type>article</type><title>Interleukin-20 as a Target in Psoriasis Treatment</title><source>MEDLINE</source><source>Access via Wiley Online Library</source><creator>STENDERUP, KARIN ; ROSADA, CECILIA ; WORSAAE, ANNE ; CLAUSEN, JES THORN ; NORMAN DAM, TOMAS</creator><creatorcontrib>STENDERUP, KARIN ; ROSADA, CECILIA ; WORSAAE, ANNE ; CLAUSEN, JES THORN ; NORMAN DAM, TOMAS</creatorcontrib><description>: Interleukin‐20 (IL‐20) is a new member of the IL‐10 cytokine family discovered by a structural algorithm. IL‐20 transgenic mice displayed skin abnormalities reminiscent of psoriasis, a finding that has prompted the investigation of this new interleukin in relation to this disease. This article reviews the role of IL‐20 and its implication in psoriasis. It is shown that IL‐20 and its receptors are found in human skin and that IL‐20 is involved in proliferation, angiogenesis, and chemotaxis, all characteristics of psoriasis. We demonstrated that IL‐20 induced the thickening of human epidermis in vivo; however, this thickening does not seem to be related to a direct effect of IL‐20 on hyperproliferation since the growth of normal human epidermal keratinocytes (NHEKs) cultured in vitro was not affected by IL‐20. On the other hand, in vitro, IL‐20 stimulated human peripheral blood mononuclear cells (PBMCs) to produce proinflammatory cytokines and, in vivo, IL‐20 in combination with PBMCs induced psoriasis. This may suggest that IL‐20 indirectly exerts its proliferative effects on keratinocytes via immune cells present in the skin. Finally, we found that blocking IL‐20 signaling in psoriasis improves psoriasis, suggesting that IL‐20 is a potential target in psoriasis treatment.</description><identifier>ISSN: 0077-8923</identifier><identifier>EISSN: 1749-6632</identifier><identifier>EISSN: 1930-6547</identifier><identifier>DOI: 10.1196/annals.1423.039</identifier><identifier>PMID: 17911452</identifier><language>eng</language><publisher>Malden, USA: Blackwell Publishing Inc</publisher><subject>Animals ; Cell Proliferation ; human keratinocytes ; Humans ; interleukin-20 ; Interleukins - immunology ; Interleukins - metabolism ; PBMCs ; psoriasis ; Psoriasis - immunology ; Psoriasis - metabolism ; Psoriasis - pathology ; Psoriasis - therapy ; Receptors, Interleukin - immunology ; Signal Transduction ; skin</subject><ispartof>Annals of the New York Academy of Sciences, 2007-09, Vol.1110 (1), p.368-381</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4749-9d4c669f0c9ba0dde69cbfa683e9e09e1ae4a9d6fd27a181b375cfe86c388d1d3</citedby><cites>FETCH-LOGICAL-c4749-9d4c669f0c9ba0dde69cbfa683e9e09e1ae4a9d6fd27a181b375cfe86c388d1d3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1196%2Fannals.1423.039$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1196%2Fannals.1423.039$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1417,27924,27925,45574,45575</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/17911452$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>STENDERUP, KARIN</creatorcontrib><creatorcontrib>ROSADA, CECILIA</creatorcontrib><creatorcontrib>WORSAAE, ANNE</creatorcontrib><creatorcontrib>CLAUSEN, JES THORN</creatorcontrib><creatorcontrib>NORMAN DAM, TOMAS</creatorcontrib><title>Interleukin-20 as a Target in Psoriasis Treatment</title><title>Annals of the New York Academy of Sciences</title><addtitle>Ann N Y Acad Sci</addtitle><description>: Interleukin‐20 (IL‐20) is a new member of the IL‐10 cytokine family discovered by a structural algorithm. IL‐20 transgenic mice displayed skin abnormalities reminiscent of psoriasis, a finding that has prompted the investigation of this new interleukin in relation to this disease. This article reviews the role of IL‐20 and its implication in psoriasis. It is shown that IL‐20 and its receptors are found in human skin and that IL‐20 is involved in proliferation, angiogenesis, and chemotaxis, all characteristics of psoriasis. We demonstrated that IL‐20 induced the thickening of human epidermis in vivo; however, this thickening does not seem to be related to a direct effect of IL‐20 on hyperproliferation since the growth of normal human epidermal keratinocytes (NHEKs) cultured in vitro was not affected by IL‐20. On the other hand, in vitro, IL‐20 stimulated human peripheral blood mononuclear cells (PBMCs) to produce proinflammatory cytokines and, in vivo, IL‐20 in combination with PBMCs induced psoriasis. This may suggest that IL‐20 indirectly exerts its proliferative effects on keratinocytes via immune cells present in the skin. Finally, we found that blocking IL‐20 signaling in psoriasis improves psoriasis, suggesting that IL‐20 is a potential target in psoriasis treatment.</description><subject>Animals</subject><subject>Cell Proliferation</subject><subject>human keratinocytes</subject><subject>Humans</subject><subject>interleukin-20</subject><subject>Interleukins - immunology</subject><subject>Interleukins - metabolism</subject><subject>PBMCs</subject><subject>psoriasis</subject><subject>Psoriasis - immunology</subject><subject>Psoriasis - metabolism</subject><subject>Psoriasis - pathology</subject><subject>Psoriasis - therapy</subject><subject>Receptors, Interleukin - immunology</subject><subject>Signal Transduction</subject><subject>skin</subject><issn>0077-8923</issn><issn>1749-6632</issn><issn>1930-6547</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2007</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkMFPwjAUhxujEUTP3sxO3gZ97WjXI6AiCUETUeOp6bY3MxkD2y3Kf-_miB459fL9vtd8hFwC7QMoMTBFYXLXh4DxPuXqiHRBBsoXgrNj0qVUSj9UjHfImXMflAILA3lKOiAVQDBkXQKzokSbY7XKCp9RzzjPeEtj37H0ssJ7dBubGZc5b2nRlGssynNyktY38WL_9sjz3e1ycu_PH6azyWjux0HzBZUEsRAqpbGKDE0SFCqOUiNCjgqpQjAYGJWINGHSQAgRl8M4xVDEPAwTSHiPXLferd18VuhKvc5cjHluCtxUTtcmLhnlB0FGh4oF0ICDFoztxjmLqd7abG3sTgPVTU7d5tRNTl3nrBdXe3UVrTH55_f9aoC3wFeW4-6QTy_eRk-_Wr9dZa7E77-VsSstZN1Bvy6mmoIcT8YvNzrkPyeOkEk</recordid><startdate>200709</startdate><enddate>200709</enddate><creator>STENDERUP, KARIN</creator><creator>ROSADA, CECILIA</creator><creator>WORSAAE, ANNE</creator><creator>CLAUSEN, JES THORN</creator><creator>NORMAN DAM, TOMAS</creator><general>Blackwell Publishing Inc</general><scope>BSCLL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>H94</scope><scope>7X8</scope></search><sort><creationdate>200709</creationdate><title>Interleukin-20 as a Target in Psoriasis Treatment</title><author>STENDERUP, KARIN ; ROSADA, CECILIA ; WORSAAE, ANNE ; CLAUSEN, JES THORN ; NORMAN DAM, TOMAS</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4749-9d4c669f0c9ba0dde69cbfa683e9e09e1ae4a9d6fd27a181b375cfe86c388d1d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2007</creationdate><topic>Animals</topic><topic>Cell Proliferation</topic><topic>human keratinocytes</topic><topic>Humans</topic><topic>interleukin-20</topic><topic>Interleukins - immunology</topic><topic>Interleukins - metabolism</topic><topic>PBMCs</topic><topic>psoriasis</topic><topic>Psoriasis - immunology</topic><topic>Psoriasis - metabolism</topic><topic>Psoriasis - pathology</topic><topic>Psoriasis - therapy</topic><topic>Receptors, Interleukin - immunology</topic><topic>Signal Transduction</topic><topic>skin</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>STENDERUP, KARIN</creatorcontrib><creatorcontrib>ROSADA, CECILIA</creatorcontrib><creatorcontrib>WORSAAE, ANNE</creatorcontrib><creatorcontrib>CLAUSEN, JES THORN</creatorcontrib><creatorcontrib>NORMAN DAM, TOMAS</creatorcontrib><collection>Istex</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Annals of the New York Academy of Sciences</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>STENDERUP, KARIN</au><au>ROSADA, CECILIA</au><au>WORSAAE, ANNE</au><au>CLAUSEN, JES THORN</au><au>NORMAN DAM, TOMAS</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Interleukin-20 as a Target in Psoriasis Treatment</atitle><jtitle>Annals of the New York Academy of Sciences</jtitle><addtitle>Ann N Y Acad Sci</addtitle><date>2007-09</date><risdate>2007</risdate><volume>1110</volume><issue>1</issue><spage>368</spage><epage>381</epage><pages>368-381</pages><issn>0077-8923</issn><eissn>1749-6632</eissn><eissn>1930-6547</eissn><abstract>: Interleukin‐20 (IL‐20) is a new member of the IL‐10 cytokine family discovered by a structural algorithm. IL‐20 transgenic mice displayed skin abnormalities reminiscent of psoriasis, a finding that has prompted the investigation of this new interleukin in relation to this disease. This article reviews the role of IL‐20 and its implication in psoriasis. It is shown that IL‐20 and its receptors are found in human skin and that IL‐20 is involved in proliferation, angiogenesis, and chemotaxis, all characteristics of psoriasis. We demonstrated that IL‐20 induced the thickening of human epidermis in vivo; however, this thickening does not seem to be related to a direct effect of IL‐20 on hyperproliferation since the growth of normal human epidermal keratinocytes (NHEKs) cultured in vitro was not affected by IL‐20. On the other hand, in vitro, IL‐20 stimulated human peripheral blood mononuclear cells (PBMCs) to produce proinflammatory cytokines and, in vivo, IL‐20 in combination with PBMCs induced psoriasis. This may suggest that IL‐20 indirectly exerts its proliferative effects on keratinocytes via immune cells present in the skin. Finally, we found that blocking IL‐20 signaling in psoriasis improves psoriasis, suggesting that IL‐20 is a potential target in psoriasis treatment.</abstract><cop>Malden, USA</cop><pub>Blackwell Publishing Inc</pub><pmid>17911452</pmid><doi>10.1196/annals.1423.039</doi><tpages>14</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0077-8923 |
| ispartof | Annals of the New York Academy of Sciences, 2007-09, Vol.1110 (1), p.368-381 |
| issn | 0077-8923 1749-6632 1930-6547 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_68337203 |
| source | MEDLINE; Access via Wiley Online Library |
| subjects | Animals Cell Proliferation human keratinocytes Humans interleukin-20 Interleukins - immunology Interleukins - metabolism PBMCs psoriasis Psoriasis - immunology Psoriasis - metabolism Psoriasis - pathology Psoriasis - therapy Receptors, Interleukin - immunology Signal Transduction skin |
| title | Interleukin-20 as a Target in Psoriasis Treatment |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-02T20%3A48%3A28IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Interleukin-20%20as%20a%20Target%20in%20Psoriasis%20Treatment&rft.jtitle=Annals%20of%20the%20New%20York%20Academy%20of%20Sciences&rft.au=STENDERUP,%20KARIN&rft.date=2007-09&rft.volume=1110&rft.issue=1&rft.spage=368&rft.epage=381&rft.pages=368-381&rft.issn=0077-8923&rft.eissn=1749-6632&rft_id=info:doi/10.1196/annals.1423.039&rft_dat=%3Cproquest_cross%3E68337203%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=20592413&rft_id=info:pmid/17911452&rfr_iscdi=true |